RESUMEN
Wild fish populations are currently experiencing unprecedented pressures, which are projected to intensify in the coming decades. Developing a thorough understanding of the influences of both biotic and abiotic factors on fish populations is a salient issue in contemporary fish conservation and management. During the 50th Anniversary Symposium of The Fisheries Society of the British Isles at the University of Exeter, UK, in July 2017, scientists from diverse research backgrounds gathered to discuss key topics under the broad umbrella of 'Understanding Fish Populations'. Below, the output of one such discussion group is detailed, focusing on tools used to investigate natural fish populations. Five main groups of approaches were identified: tagging and telemetry; molecular tools; survey tools; statistical and modelling tools; tissue analyses. The appraisal covered current challenges and potential solutions for each of these topics. In addition, three key themes were identified as applicable across all tool-based applications. These included data management, public engagement, and fisheries policy and governance. The continued innovation of tools and capacity to integrate interdisciplinary approaches into the future assessment and management of fish populations is highlighted as an important focus for the next 50 years of fisheries research.
Asunto(s)
Explotaciones Pesqueras , Peces/fisiología , Animales , Congresos como Asunto , Conservación de los Recursos Naturales/métodos , Comunicación Interdisciplinaria , Modelos Biológicos , Políticas , Dinámica Poblacional , TelemetríaRESUMEN
We designed a new semi-quantitative competitor-based PCR assay to assess the amount of p190 BCR-ABL mRNA in patients with Ph-positive ALL. Transcript numbers were compared in 29 paired specimens of blood and marrow collected contemporaneously from 18 patients at differing stages of disease. In general, the numbers of BCR-ABL transcripts detected in marrow in blood were not significantly different (p = 0.1). However, in four samples BCR-ABL transcripts (< 10-1000/micrograms RNA) were detected in the marrow while the blood was negative; the reverse, positive blood and negative marrow, was not seen. In a further three samples the number of BCR-ABL transcripts was more than 10-fold higher in the marrow. We measured the number of ABL transcripts/micrograms RNA in all samples as an internal standard in order to control for variations in sample quality and other parameters. For two out of the four discordant samples in which blood was PCR negative, the number of ABL transcripts/micrograms RNA detected in the marrow was substantially higher than in the blood, suggesting poor quality blood specimens. However, the ratio of BCR-ABL to ABL in marrow and blood was similar for the three discordant samples in which both tissues were PCR positive. We conclude that in general, blood and marrow contain similar BCR-ABL transcript numbers in Ph-positive ALL but some samples are discordant. Marrow is therefore the preferred tissue for residual disease studies. Quantification of ABL mRNA as an internal control is useful in the interpretation of competitive PCR data and may serve as a robust way to standardize results between laboratories.
Asunto(s)
Células Sanguíneas/patología , Médula Ósea/patología , Proteínas de Fusión bcr-abl/genética , Células Madre Neoplásicas/patología , Cromosoma Filadelfia , Reacción en Cadena de la Polimerasa , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Secuencia de Bases , Proteínas de Fusión bcr-abl/análisis , Humanos , Datos de Secuencia Molecular , Neoplasia Residual , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangre , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proteínas Proto-Oncogénicas c-abl/análisis , ARN Mensajero/análisis , ARN Neoplásico/análisis , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
CEA, SCC and CYFRA 21-1 were measured in samples of serum coming from 105 'Non small cell lung cancer' (NSCLC) patients. The present study has been carried out to compare these markers, to analyse their prognostic significance and to determine the best combination of tumor markers. The median value and interquartile range were: CYFRA 21-1: 2,3 ng/ml, CEA: 3,7 ng/ml, SCC: 1,2 ng/ml. CEA demonstrated higher values in adenocarcinomas (P = 0.04). SCC and CYFRA 21-1 were comparable in the different histologic groups. CYFRA 21-1 and CEA values were dependant on tumor stage. Advanced tumors (T3 and T4) demonstrated higher serum CYFRA 21-1 level (P = 0.0006). CYFRA 21-1 was higher than 3,3 ng/ml in 36% of patients. CEA was higher than 5 ng/ml in 38% of patients and SCC was higher than 2 ng/ml in 27% of patients. Patients with a high CEA and CYFRA21-1 serum level had a shorter survival than those with a normal serum level. In a Cox regression analysis four variables (TNM stage, age, CYFRA 21-1 and CEA level) were found to be significant in the prediction of survival; CYFRA 21-1 level had the lowest P value (P = 0.0002). The current study suggests the use of a combination of CEA and CYFRA 21-1 in the clinical care of NSCLC.
Asunto(s)
Antígenos de Neoplasias/sangre , Biomarcadores de Tumor/sangre , Antígeno Carcinoembrionario/sangre , Carcinoma de Pulmón de Células no Pequeñas/sangre , Queratinas/sangre , Neoplasias Pulmonares/sangre , Serpinas , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/inmunología , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/patología , Femenino , Humanos , Queratina-19 , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Pronóstico , Modelos de Riesgos Proporcionales , Análisis de SupervivenciaRESUMEN
We report the unusual complication of vaginal stenosis occurring after allogeneic bone marrow transplantation (BMT) for leukaemia. This was in all likelihood a manifestation of chronic graft-versus-host disease (cGVHD), although the patient has no other stigmata of this and suffered little acute graft-versus-host disease (aGVHD) after BMT. Other risk factors for vaginal stenosis were considered and appear to be absent in this patient, although the total body irradiation used as part of her conditioning therapy may play a role. We suggest that vaginal stenosis may be under-reported, since female patients suffer a number of gynaecological complications after BMT, and that regular questioning and examination may aid in making an earlier diagnosis, allowing speedier instigation of therapy and thus improving quality of life.
Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Leucemia Mieloide/terapia , Enfermedades Vaginales/etiología , Enfermedad Aguda , Adulto , Femenino , Hematocolpos/etiología , Hematocolpos/fisiopatología , Humanos , Trasplante Homólogo , Enfermedades Vaginales/fisiopatologíaRESUMEN
A rapid method for the determination of urinary oxalic acid by gas-liquid chromatography is described. The procedure involves extraction of oxalate from urine by tetrahydrofuran followed by evaporation to dryness and subsequent with diesterification with the boron-trifluoride propanol. The derivative is extracted with hexane and is detected by FID gas chromatography. Malonic acid is used as internal standard. Analytical recovery ranged from 94 to 105%. The coefficient of variation in replicate aliquots over the entire range is less than 6%. The expected range for our method is calculated to be 44 to 577 mumol of oxalate per 24-h urine.
Asunto(s)
Oxalatos/orina , Cromatografía de Gases , Ionización de Llama , Humanos , Valores de ReferenciaRESUMEN
BACKGROUND: Autologous bone marrow transplantation (ABMT) is frequently used in the treatment of malignant disease but carries the risk of reintroducing tumor cells into the patient. Methods are required for removing malignant cells from harvested bone marrow (BM) without impairing hematopoietic reconstitution. We have shown that simvastatin is toxic to leukemic progenitor cells at a concentration that conserves normal BM progenitors and may be of use clinically as a novel BM purging agent. METHODS: A two-stage culture system was used to compare the effects of simvastatin on both normal BM progenitor and primary acute myeloid leukemia (AML) cells. AML cells and normal BM mononuclear cells were incubated for 18 hours in suspension culture with 10 micrograms per mL simvastatin and the numbers of surviving clonogenic progenitor cells assayed in semisolid agar culture. RESULTS: Following simvastatin treatment of 18 AML cell populations, the mean surviving fraction of progenitor cells was 21.3 +/- 4.8% ( +/- standard error of the mean [SEM]). In contrast, the mean survival of normal BM progenitors from 16 donors was 89.6 +/- 8.6% ( +/- SEM). Samples were taken from 6 AML patients before treatment and after remission of disease had been induced by chemotherapy. In 5 of these cases the AML sample was significantly more sensitive to simvastatin than the remission sample, 4 of the 5 showed > 80% difference in progenitor cell survival. CONCLUSIONS: AML progenitor cells are sensitive to a short-term exposure to simvastatin that spares normal BM hematopoietic progenitor cells. We conclude that simvastatin may be an effective in vitro purging agent in ABMT for AML.
Asunto(s)
Purgación de la Médula Ósea/métodos , Trasplante de Médula Ósea/métodos , Médula Ósea/efectos de los fármacos , Leucemia Mieloide/patología , Lovastatina/análogos & derivados , Enfermedad Aguda , Muerte Celular , Células Cultivadas , Humanos , Lovastatina/farmacología , Inducción de Remisión , Simvastatina , Trasplante AutólogoRESUMEN
UNLABELLED: Experimental study of rhabdomyosarcoma with successive transplantation upon C3H/He mice, treated by irradiation (Co 60) and combined irradiation-hyperbaric oxygen (HBO), dating from 3, 14 and 15 days after transplantation. The data (tumor volume evolution, histological modifications, pulmonary metastases) are compared with controls. CONCLUSIONS: curative radiotherapy depends on starting treatment as soon as possible with or without HBO. After the 14th day, sensitisation to combined HBO and C60 is seen. The extension of pulmonary metastases is a function of tumor growth. Paradoxically metastases were less frequent after HBO only and more frequent after HBO-Co 60.
Asunto(s)
Radioisótopos de Cobalto/uso terapéutico , Oxigenoterapia Hiperbárica , Rabdomiosarcoma/terapia , Animales , Femenino , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Ratones , Ratones Endogámicos C3H , Trasplante de Neoplasias , Neoplasias Experimentales/terapia , Rabdomiosarcoma/radioterapia , Factores de TiempoRESUMEN
We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients. A favourable clinical response rate was achieved in 28/38 (74%) patients receiving teicoplanin plus ciprofloxacin and in 17/35 (49%) of those receiving gentamicin plus piperacillin (P = 0.05). Microbiologically documented infections accounted for 55% of febrile events. When these episodes were analysed separately, response to teicoplanin plus ciprofloxacin remained unchanged at 74% whereas only 35% patients responded to gentamicin and pieracilin (P = 0.034). Gram-positive organisms accounted for 78% bacterial isolates with Staphylococcus epidermidis the most common pathogen. Ten out of 12 (83%) Staph. epidermidis infections resolved when treated with teicoplanin and ciprofloxacin as compared with a response rate of only two out of eight (25%) with gentamicin and piperacillin (P = 0.032). The combination of teicoplanin and ciprofloxacin was associated with no severe drug-related adverse events; by contrast, two patients receiving gentamicin plus piperacilin were withdrawn owing to adverse drug reactions, one with acute renal failure and one following a severe allergic reaction to piperacillin. We conclude that teicoplanin with ciprofloxacin is more effective than gentamicin plus piperacillin for the empirical treatment of febrile neutropenic patients. The high incidence of Gram-positive infection in our unit probably justifies the use of a specific anti-Gram-positive agent in the first-line antibiotic regimen.
Asunto(s)
Antibacterianos/uso terapéutico , Ciprofloxacina/uso terapéutico , Fiebre/tratamiento farmacológico , Gentamicinas/uso terapéutico , Piperacilina/uso terapéutico , Bacterias/aislamiento & purificación , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/microbiología , Trasplante de Médula Ósea , Quimioterapia Combinada , Fiebre/microbiología , Glicopéptidos/uso terapéutico , Enfermedades Hematológicas/tratamiento farmacológico , Humanos , Neutropenia/complicaciones , Estudios Prospectivos , TeicoplaninaRESUMEN
The investigation of methyl (2,2-diphenyl)-vinyl sulfone (14C-MDVS) administered i.p. in mice shows that this product appears rapidly in the general circularoty system. The blood concentration of MDVS reaches a maximum 1 h after injection. Part of the MDVS is bound to the plasma proteins. Infrared spectrometry analysis of radioactive products eliminated by the urine confirms that the product is not split, but also reveals the presence of hydroxyl and carbonyl groups in the metabolic conversion products.
Asunto(s)
Sulfonas/metabolismo , Animales , Eritrocitos/metabolismo , Femenino , Ratones , Unión Proteica , Factores de Tiempo , Distribución Tisular , Compuestos de Vinilo/metabolismoRESUMEN
Benzimidazoles show important radioprotecting activity. Structure-activity relationships (radioprotective activity and toxicity) are given for benzimidazole-2 derivatives.
Asunto(s)
Bencimidazoles/farmacología , Protectores contra Radiación , Animales , Bencimidazoles/síntesis química , Bencimidazoles/toxicidad , Cromatografía en Capa Delgada , Dosificación Letal Mediana , Ratones , Ratones Endogámicos C3H , Modelos Biológicos , Protectores contra Radiación/síntesis química , Protectores contra Radiación/toxicidad , Relación Estructura-ActividadRESUMEN
CA 125, tumor marker newly appeared, is used in ovarian carcinomas. Its determination in serum is an important progress, not only in diagnosis but above all at the time of monitoring of clinical course during the treatment. The determination is possible with immunoradiometric assay (IRA) or enzyme immunoassay (EIA). The comparative study show a good correlation between these two methods. Both give comparable results. The choice for either method depends on equipment of laboratory.
Asunto(s)
Antígenos de Neoplasias/análisis , Biomarcadores de Tumor/sangre , Técnicas para Inmunoenzimas , Neoplasias Ováricas/sangre , Radioinmunoensayo , Adulto , Anciano , Femenino , Humanos , Persona de Mediana EdadRESUMEN
We have used interphase fluorescence in situ hybridization (IFISH) to detect trisomy 8, trisomy 9 and 20q deletion in circulating granulocytes from patients with polycythaemia vera (PV). Out of 64 PV patients, 15 (23%) exhibited an abnormality. Two patients had trisomy 9, three had trisomy 8 and 10 patients had hemizygous deletion of D20S108 (a locus in the 20q common deleted region). Aberrant nuclei ranged from 10% to 80% in these 15 cases. There was no correlation between the presence of a marker and sex, age, interval between presentation and IFISH analysis, neutrophil or platelet count or therapy. Conventional marrow cytogenetic karyotype results were available in 23 cases and there was concurrence between these and blood IFISH in 16 cases (13 normal and three with 20q/D20S108 deletion by both methods). Three patients with D20S108 deletion by IFISH were normal by previous marrow cytogenetic testing and four cases with 20q deletion by previous marrow cytogenetics had normal blood granulocytes according to IFISH. Thus, we confirm that trisomies 8 and 9 and deletion of 20q are diagnostically useful markers of PV. IFISH analysis of blood granulocytes is a practical method for detecting these markers, but as an adjunct to, not as a substitute for, conventional marrow cytogenetics.
Asunto(s)
Cromosomas Humanos Par 8 , Cromosomas Humanos Par 9 , Eliminación de Gen , Policitemia Vera/genética , Trisomía , Adulto , Anciano , Anciano de 80 o más Años , Análisis Citogenético , Femenino , Marcadores Genéticos , Granulocitos , Humanos , Hibridación Fluorescente in Situ , Interfase , Masculino , Persona de Mediana EdadRESUMEN
Considering the current need to improve cost-effectiveness in cancer patient management, a prospective study was undertaken in order to define the optimal combination of bone scan and tumour marker assays in breast and lung cancer strategies, as has been done in the case of prostate cancer. All patients with breast or lung cancer referred to the Nuclear Medicine Department of the Grenoble Teaching Hospital between December 1995 and April 1997 were included. A blood sample was drawn in each case for marker assay (CA15-3 or CEA and CYFRA 21-1) on the same day as the bone scan. Two hundred and seventy-five patients were included: 118 with lung cancer and 157 with breast cancer. With regard to lung cancer, no information useful for guiding bone scan prescription was obtained through CEA and CYFRA 21-1 assays. For breast cancer, the results suggest that in asymptomatic patients, a CA15-3 level of less than 25 U/ml (upper normal value chosen as the threshold) is strongly predictive of a negative bone scan; by contrast, high tumour marker levels are predictive of neoplastic bone involvement. When a doubtful bone scan is obtained in a patient with breast cancer, a normal marker level makes it highly probable that bone scan abnormalities are not related to malignancy.